EGFR and adenocarcinoma: The frequency of EGFR mutations was higher in patients with adenocarcinoma than in those with non-adenocarcinoma (adenocarcinoma vs. non-adenocarcinoma, 48.1% vs. 18.5%, P = 0.023).